In the context of tumors, OPN can activate the integrin α5 pathway, stimulating the FAK/AKT and ERK signaling pathways in tumor cells and thereby promoting the proliferation and drug resistance of non-small cell lung cancer (NSCLC) cells (102). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.